| Bioactivity | BMS-250749 is a fluoroglycosyl-3,9-difluoroindolcarbazole topoisomerase I inhibitor with potent in vitro and in vivo preclinical properties. BMS-250749 exhibits potent topoisomerase I activity, cytotoxicity, and selectivity. BMS-250749 exhibits broad-spectrum antitumor activity superior to CPT-11 in certain preclinical xenograft models. BMS-250749 shows curative antitumor activity against Lewis lung cancer. BMS-250749 is the lead clinical candidate in a series of fluoroglycosylated fluoroindolecarbazoles[1]. |
| Target | Topoisomerase I |
| CAS | 230640-88-7 |
| Formula | C15H19N3O2 |
| Molar Mass | 273.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
BMS-284640
CAS: 230640-88-7 F: C15H19N3O2 W: 273.33
BMS-250749 is a fluoroglycosyl-3,9-difluoroindolcarbazole topoisomerase I inhibitor with potent in vitro and in vivo pre
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.